Navigation Links
Anthera Pharmaceuticals Reports 2010 Third Quarter Financial Results and Operational Update
Date:11/2/2010

progress with potential manufacturing partners for Phase 3.

In conjunction with the release of financial results for the third quarter ended September 30, 2010, Anthera will host a conference call at 5 pm Eastern Time, November 2, 2010. U.S. and Canadian participants may dial (877) 312-8807; international participants may dial (253) 237-1190. The conference ID is 19111226. To access the 24-hour audio replay, U.S. and Canadian participants may dial (800) 642-1687; international participants may dial (706) 645-9291. The conference ID for the replay is 19111226. The audio replay will be available until November 9, 2010. This conference call will be webcast live and archived on Anthera's website until November 2, 2011, www.anthera.com.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, varespladib, and two Phase 2 clinical programs, A-623 and A-001. Varespladib and A-001 inhibit a novel enzyme target known as sPLA2 . Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator, or (BAFF), which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus). For more information, please visit www.anthera.com.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements made pursuant to the safe harbor pr
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Announces Third Quarter 2010 Financial Report and Conference Call
2. Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing
3. Anthera Pharmaceuticals to Present at Deutsche Bank Securities 35th Annual Health Care Conference
4. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
5. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
6. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
8. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
9. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
11. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  eRelevance Corporation ( ... announced today that it has completed integration with ... for Plastic Surgery and Dermatology practices. ... value to healthcare practices using Nextech," stated ... Corporation. "Using information from the EMR we are ...
(Date:8/21/2014)... /CNW/ - Eisai Limited is pleased to support the Canadian ... book available in Canada . The comic ... educate children and their parents about epilepsy, the most common ... than 300,000 Canadians. Eisai is guided by a corporate philosophy ... the patient is central – there was a need within ...
(Date:8/21/2014)... /PRNewswire-iReach/ -- Inc. magazine today ranked ... straight year, No. 349 in Health on its ... the nation,s fastest-growing private companies. The list represents ... segment of the economy—America,s independent entrepreneurs. Companies such ... Zillow, and many other well-known names gained early ...
Breaking Medicine Technology:eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3
... DIEGO, Jan. 10, 2011 Optimer Pharmaceuticals, Inc. (Nasdaq: ... Linda Amper, Ph.D., as Senior Vice President of Human ... Economics & Outcomes Research (HEOR), and John Womelsdorf, Ph.D., ... will strengthen the management team as the Company prepares ...
... Calif., Jan. 10, 2011 OncoMed Pharmaceuticals, Inc., ... today announced that patient dosing has commenced in a Phase ... tumor cancers.   OMP-59R5 is a monoclonal antibody ... to specifically block these targets to enter human studies.  The ...
Cached Medicine Technology:Optimer Pharmaceuticals Announces Key Additions to Management Team 2Optimer Pharmaceuticals Announces Key Additions to Management Team 3Optimer Pharmaceuticals Announces Key Additions to Management Team 4OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5 2OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5 3
(Date:8/22/2014)... patients who need surgery for facial pain caused by ... often used, reports a study in the September issue ... the Congress of Neurological Surgeons . The journal ... a part of Wolters Kluwer Health . , ... much lower cost than other types of surgical treatments ...
(Date:8/22/2014)... August 22, 2014 “Dr. Luciana Show – ... , aka Dr. Luciana, is finding it challenging to stay ... while taking care of hundreds of students, so the editing ... the show is completed, and she recently entered it into ... including those of her husband, actor/screenwriter Gregory Graham , ...
(Date:8/22/2014)... 22, 2014 The report "Higher ... Security & Compliance, Campus Technology, Student & Curriculum, ... (2014-2019)", defines and segments the global Higher Ed ... and forecasting of market sizes. The report also ... and opportunities impacting it along with the adoption ...
(Date:8/22/2014)... However, these are two entirely different mechanisms that occur ... digest lactose properly because they lack an enzyme known ... more dangerous cow milk allergy, however, the body,s immune ... , According to statistics, about two to three percent ... allergy. Less adults are diagnosed with the disease. The ...
(Date:8/22/2014)... August 22, 2014 This funding was ... research affiliate, Saneron CCEL Therapeutics, Inc. in the form ... is extremely pleased to collaborate with Saneron on several ... we hope will lead to regenerative therapies using ... as ALS,” David Portnoy, Chairman and Co-CEO of Cryo-Cell, ...
Breaking Medicine News(10 mins):Health News:More common procedures for painful facial tics carry high costs, reports study in Neurosurgery 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 3Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 4Health News:Higher Education Market Worth $65.83 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Higher Education Market Worth $65.83 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Higher Education Market Worth $65.83 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Scientists uncover why major cow milk allergen is actually allergenic 2Health News:Cryo-Cell Provides Funding for Cord Blood Clinical Trial Application to Treat ALS 2Health News:Cryo-Cell Provides Funding for Cord Blood Clinical Trial Application to Treat ALS 3
... psoriasis condition are more likely to smoke, and smoking contributes ... scaling of the skin, and affect places like legs, scalp, ... of the feet. The chances of people with psoriasis suffering ... published in the Archives of Dermatology. ,Data ...
... Co, known as MSD India, has entered into a collaboration ... studies on the former's investigational cervical cancer drug, Gardasil.// ... India. Under the agreement, clinical trials will be conducted for ... ,The vaccine that has been developed by Merck and ...
... Rutgers, The State University of New Jersey have come ... related to determining the quality of mate in humans.// ... in choosing mates among many animal species. Impressive dancers ... ,Rutgers in association with computer scientist at the University ...
... sitting or lying down is a treatable health problem, but ... ,The condition, called Restless Legs Syndrome (RLS), makes it ... long drives or even while watching a movie, say experts., ... which is accompanied in many cases by a tingling and ...
... Department of Health and Mental Hygiene (DOHMH) has banned at ... "dangerous levels" of lead and mercury. // , ,"Though ... Board of the Institute of Medicine of the National Academies ... ppm (parts per million) of lead and no more than ...
... we took note and took care of mother nature. ... USA.,It is called the Canon National Parks Science Scholars ... eight doctoral students -- from Canada to Chile, and ... are receiving significant multi-year scholarships this year to conduct ...
Cached Medicine News:Health News:Merck, ICMR to conduct joint trials on cervical cancer vaccine 2Health News:Shaking Legs Syndrome Is Curable 2Health News:NY Health Dept Bans 3 Ayurveda Drugs 2Health News:Time to wake up as conservationists 2Health News:Time to wake up as conservationists 3
0.2 mm hook with curved shaft to reach over lens optic. Flat serrated handle with polished finish. Overall length: 4.8 inches. Most popular size or model....
Angled 45 degrees, 10 mm shaft with 0.2 mm tip. Round knurled handle with dull finish. Overall length: 4.6 inches....
Straight 31 mm shaft with flat handle and polished finish. 0.5 mm cup. Overall length: 5 inches....
0.5 mm curette cup, reverse side of sandblasted to polish capsule. Round knurled handle with polished finish. Overall length: 5 inches....
Medicine Products: